Drugs / HBT-708
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06993870 | Jun 2025 → Mar 2026 overdue | cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBT-708 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06993870 ↗ |
| Route | Intravenous | “The administration frequencies of HBT-708 is Q3W i.v.” NCT06993870 ↗ |